Regulation of self-renewal in normal and cancer stem cells

被引:44
|
作者
Falzacappa, Maria V. Verga [1 ]
Ronchini, Chiara [2 ]
Reavie, Linsey B. [1 ]
Pelicci, Pier G. [1 ]
机构
[1] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy
[2] IIT, Ctr Genom Sci IIT SEMM, Milan, Italy
关键词
asymmetric division; cancer stem cell; cancer therapy; DNA damage; genomic instability; p53; p21; self-renewal; stem cell; symmetric division; ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; FUNCTIONAL MAMMARY-GLAND; TUMOR-INITIATING CELLS; BLAST-CRISIS CML; HEMATOPOIETIC STEM; IN-VIVO; PROGENITOR CELLS; BREAST-CANCER;
D O I
10.1111/j.1742-4658.2012.08727.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations can confer a selective advantage on specific cells, enabling them to go through the multistep process that leads to malignant transformation. The cancer stem cell hypothesis postulates that only a small pool of low-cycling stem-like cells is necessary and sufficient to originate and develop the disease. Normal and cancer stem cells share important functional similarities such as self-renewal and differentiation potential. However, normal and cancer stem cells have different biological behaviours, mainly because of a profound deregulation of self-renewal capability in cancer stem cells. Differences in mode of division, cell-cycle properties, replicative potential and handling of DNA damage, in addition to the activation/inactivation of cancer-specific molecular pathways confer on cancer stem cells a malignant phenotype. In the last decade, much effort has been devoted to unravel the complex dynamics underlying cancer stem cell-specific characteristics. However, further studies are required to identify cancer stem cell-specific markers and targets that can help to confirm the cancer stem cell hypothesis and develop novel cancer stem cell-based therapeutic approaches.
引用
收藏
页码:3559 / 3572
页数:14
相关论文
共 50 条